Patents by Inventor Jacob Edward Wulff

Jacob Edward Wulff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOMATED SAMPLE QUALITY ASSESSMENT
    Publication number: 20210088539
    Abstract: A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 25, 2021
    Inventors: Adam D. Kennedy, Matthew W. MITCHELL, Meredith V. Brown, Kay A. Lawton, Shaun Lonergan, Jacob Edward Wulff
  • Determining liver toxicity of an agent using metabolite biomarkers
    Patent number: 8658351
    Abstract: The present invention provides various biomarkers for hepatotoxicity and various methods of using the biomarkers Some of the biomarkers within the scope of this invention are cholate, glycochenodeoxycholate, glycocholate, taurine, 3-hyroxy-2-ethylpropionate, 4-imidazoleacetate, tyramine, anthranilate, 2?-deoxycytidine, N-acetyl aspartate (NAA), beta-hydroxy-hexanoate, and sarcosine (N-methylglycine) The methods of using the biomarkers include exposing a first hepatocyte culture to a test agent and comparing the levels of the one or more biomarkers obtained in the first hepatocyte culture to the levels of the one or more biomarkers obtained in a second hepatocyte culture without the test agent, where differential levels of the one or more biomarkers in the first hepatocyte culture as compared to the levels in the second hepatocyte culture is indicative of the test agent being a hepatotoxicant.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: February 25, 2014
    Assignee: Metabolon, Inc.
    Inventors: Michael Milburn, Lining Guo, Jacob Edward Wulff, Kay A. Lawton
  • Determination of the Liver Toxicity of an Agent
    Publication number: 20110300571
    Abstract: The present invention provides various biomarkers for hepatotoxicity and various methods of using the biomarkers Some of the biomarkers within the scope of this invention are cholate, glycochenodeoxycholate, glycocholate, taurine, 3-hyroxy-2-ethylpropionate, 4-imidazoleacetate, tyramine, anthranilate, 2?-deoxycytidine, N-acetyl aspartate (NAA), beta-hydroxy-hexanoate, and sarcosine (N-methylglycine) The methods of using the biomarkers include exposing a first hepatocyte culture to a test agent and comparing the levels of the one or more biomarkers obtained in the first hepatocyte culture to the levels of the one or more biomarkers obtained in a second hepatocyte culture without the test agent, where differential levels of the one or more biomarkers in the first hepatocyte culture as compared to the levels in the second hepatocyte culture is indicative of the test agent being a hepatotoxicant.
    Type: Application
    Filed: February 5, 2010
    Publication date: December 8, 2011
    Inventors: Michael Milburn, Lining Guo, Jacob Edward Wulff, Kay A. Lawton